Extended-Release Pramipexole in Advanced Parkinson Disease
Neurol 77:767-774, Schapira, A.H.V.,et al, 2011
Fourteen-Year Final Report of the Randomized PDRG-UK Trial Comparing Three Treatments in PD
Neurol 71:474-480.470, Katzenschlager,R.,et al., 2008
Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999
Multicenter, Placebo-Controlled Trial of Cabergoline Taken Once Daily in the Treatment of Parkinson's Disease
Neurol 46:1062-1065, Hutton,J.T.,et al, 1996
Double-Blind Comparison of Cabergoline & Bromocriptine in Parkinson's Disease Pts with Motor Fluctuations
Neurol 47:785-788, Inzelberg,R.,et al, 1996
Drug Treatment of Parkinson's Disease
BMJ 310:575-579, Quinn,N., 1995
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Fluctuating Parkinson's Disease:Treatment with the Long-Acting Dopamine Agonist Cabergoline
Arch Neurol 51:1236-1241, Ahlskog,J.E.,et al, 1994
Multictr Study of Cabergoline, A Long-Acting Dopamine Receptor Agonist, in PD Fluct Resp to Levodopa/Carbidopa
Neurol 43:1981-1984, Lieberman,A.,et al, 1993